2018•JAMA OncologyRequires access
Biosimilar Filgrastim Use in the United States vs the European Union and Japan—Why Does It Lag Behind and What Can Be Done?
Zaina Parvez Qureshi, Sumimasa Nagai, Charles Lee Bennett
Open publisher page 8 citations
Abstract
This Viewpoint discusses obstacles that limit the use of biosimilar filgrastim in the United States compared with countries in the European Union and Japan and discusses strategies that might help biosimilar filgrastim use become more widespread.